Clinical Trials Directory

Trials / Completed

CompletedNCT02229643

Serum Neuroglobin and Nogo-A Concentrations in Acute Traumatic Brain Injury

Neuroglobin and Nogo-A as Biomarkers for the Prognosis of Closed Traumatic Brain Injury

Status
Completed
Phase
Study type
Observational
Enrollment
34 (actual)
Sponsor
Shanghai 6th People's Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Neuroglobin has been described as a marker of traumatic brain injury. Nogo-A plays an important role in mediating neuroanatomical plasticity and functional recovery following traumatic brain injury. The investigators sought to examine the changes in serum neuroglobin and Nogo-A concentrations in patients with traumatic brain injury during the initial 96-h posttraumatic period and assessed the relation of neuroglobin and Nogo-A to Glasgow Coma Score and prognosis of such patients with traumatic brain injury.

Conditions

Timeline

Start date
2012-05-01
Primary completion
2013-06-01
Completion
2014-06-01
First posted
2014-09-01
Last updated
2020-08-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02229643. Inclusion in this directory is not an endorsement.

Serum Neuroglobin and Nogo-A Concentrations in Acute Traumatic Brain Injury (NCT02229643) · Clinical Trials Directory